Increasing Male Infertility Worldwide Drives Male Infertility Market Growth

According to our new market research study titled Male Infertility Market - Global Analysis and Forecast - by Test, Treatment Type, Distribution Channel, and End User, the market is expected to reach US$ 6,213.96 million by 2027 from US$ 3,883.82 million in 2019; it is estimated to grow at a CAGR of 6.2% from 2020 to 2027. The report highlights the trends prevalent in the global male infertility market, and the drivers and deterrents pertaining to its growth. The growth of the market is mainly attributed to the increase in male infertility worldwide and technological advancements. However, the high cost of procedures hampers the growth of the market.

Infertility in males is a global issue with prevalence percentages varying from one region to another. Deficiencies in semen and poor semen quality are the prime causes of infertility in men. According to the National Institutes of Health (NIH), infertility affected ~15% couples, i.e., ~48.5 million couples, worldwide in 2016. Further, according to a research survey published in the Journal of Reproductive Biology and Endocrinology, in 2016, infertility rate among men was found to be highest in Africa and Eastern/Central Europe.

According to the World Health Organization (WHO), among ~20% of infertile couples, the problem is with male partners, whereas in 30% of couples, the issue exists in both the partners. Thus, men contribute to ~50% of the infertility cases globally. Furthermore, according to Healthy Male Andrology Australia, a division funded by Australian Government Department of Health, ~1 in 20 males produces low number of sperms, leading to infertility, and 1 in ~100 men has no sperms at all.

MERCK KGaA, Sanofi, Bayer AG, Endo Pharmaceuticals Inc., SCSA Diagnostics, Inc., Andrology Solutions, Halotech DNA, INTAS PHARMACEUTICALS LTD., Cadila Pharmaceuticals Ltd.; and Vitrolife are among the prominent players operating in the male infertility market. These players are focused on both organic and inorganic growth strategies to sustain their position in the market. For instance, in July 2019, Vitrolife entered into an agreement with Prime Tech to collaboratively develop and exclusively market the Piezo technique for enhanced ICSI procedure in human IVF in the global markets, excluding Thailand, Japan, and Malaysia. Vitrolife has initiated application procedures for regulatory approval in various markets to enable the prospective commercialization of technology.

The report segments the global male infertility market as follows:

- By Test
- DNA Fragmentation Technique
- Oxidative Stress Analysis 
- Microscopic Examination
- Sperm Agglutination
- Computer Assisted Semen Analysis
- Sperm Penetration Assay
- Others

- By Treatment Type
- Assisted Reproductive Technology and Varicocele Surgery
- Medication

- By Distribution Channel
- Hospitals Pharmacies 
- Pharmacies and Drug Stores 
- Online Pharmacies

- By End User
- Hospitals and Clinics
- Fertility Centers 
- Research Institutes 
- Other End Users

- By Geography
- North America
- Europe
- Asia Pacific (APAC)
- Middle East and Africa (MEA)
- South and Central America (SCAM)

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com